Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.virusres.2018.07.018
DC Field | Value | |
---|---|---|
dc.title | Drug repurposing of quinine as antiviral against dengue virus infection | |
dc.contributor.author | Malakar, S | |
dc.contributor.author | Sreelatha, L | |
dc.contributor.author | Dechtawewat, T | |
dc.contributor.author | Noisakran, S | |
dc.contributor.author | Yenchitsomanus, PT | |
dc.contributor.author | Chu, JJH | |
dc.contributor.author | Limjindaporn, T | |
dc.date.accessioned | 2020-08-21T05:39:16Z | |
dc.date.available | 2020-08-21T05:39:16Z | |
dc.date.issued | 2018-08-15 | |
dc.identifier.citation | Malakar, S, Sreelatha, L, Dechtawewat, T, Noisakran, S, Yenchitsomanus, PT, Chu, JJH, Limjindaporn, T (2018-08-15). Drug repurposing of quinine as antiviral against dengue virus infection. Virus Research 255 : 171-178. ScholarBank@NUS Repository. https://doi.org/10.1016/j.virusres.2018.07.018 | |
dc.identifier.issn | 01681702 | |
dc.identifier.issn | 18727492 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/173265 | |
dc.description.abstract | © 2018 Elsevier B.V. Dengue virus (DENV) disease outbreaks continue to develop across the globe with significant associated mortality and economic burden, yet no treatment has been approved to combat this virus. In an attempt to identify novel drug candidates as therapeutics for DENV infection, we evaluated four US Food and Drug Administration (FDA) approved drugs including aminolevullic acid, azelaic acid, mitoxantrone hydrochloride, and quinine sulfate, and tested their ability to inhibit DENV replication using focus-forming unit assay to quantify virus production. Of the four investigated compounds, quinine was found to have the most pronounced anti-DENV activity. Quinine inhibited DENV production of DENV by about 80% compared to untreated controls, while the other three drugs decreased virus production by only about 50%. Moreover, quinine inhibited DENV production of all four serotypes of DENV. Reduction in virus production was documented in three different cell lines of human origin. Quinine significantly inhibited DENV replication by reducing DENV RNA and viral protein synthesis in a dose-dependent manner. In addition, quinine ameliorated expression of genes related to innate immune response. These findings suggest the efficacy of quinine for stimulating antiviral genes to reduce DENV replication. The antiviral activity of quinine observed in this study may have applicability in the development of new drug therapies against DENV. | |
dc.publisher | Elsevier BV | |
dc.source | Elements | |
dc.subject | Dengue virus | |
dc.subject | Innate immune response | |
dc.subject | Quinine sulfate | |
dc.subject | Replication | |
dc.subject | Animals | |
dc.subject | Antigens, Viral | |
dc.subject | Antiviral Agents | |
dc.subject | Cell Line | |
dc.subject | Chlorocebus aethiops | |
dc.subject | Dengue | |
dc.subject | Dengue Virus | |
dc.subject | Drug Repositioning | |
dc.subject | Humans | |
dc.subject | Immunity, Innate | |
dc.subject | Models, Biological | |
dc.subject | Quinine | |
dc.subject | Serogroup | |
dc.subject | Vero Cells | |
dc.subject | Viral Load | |
dc.subject | Virus Replication | |
dc.type | Article | |
dc.date.updated | 2020-06-23T07:39:42Z | |
dc.contributor.department | MICROBIOLOGY AND IMMUNOLOGY | |
dc.description.doi | 10.1016/j.virusres.2018.07.018 | |
dc.description.sourcetitle | Virus Research | |
dc.description.volume | 255 | |
dc.description.page | 171-178 | |
dc.published.state | Published | |
dc.description.redeposit | completed | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10.pdf | Accepted version | 1.03 MB | Adobe PDF | OPEN | Post-print | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.